ArticleNeuro-oncology2023

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.

Macarena I de la Fuente et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.